What is the official website of Pfizer Medical ?

The official website of Pfizer Medical is https://www.pfizer.com/products/information.

What is Pfizer Medical's cybersecurity risk score?

Pfizer Medical has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Pfizer Medical experienced?

According to Rankiteo, Pfizer Medical currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Pfizer Medical been affected by any supply chain cyber incidents ?

According to Rankiteo, Pfizer Medical has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Pfizer Medical have SOC 2 Type 1 certification ?

According to Rankiteo, Pfizer Medical is not certified under SOC 2 Type 1.

Does Pfizer Medical have SOC 2 Type 2 certification ?

According to Rankiteo, Pfizer Medical does not hold a SOC 2 Type 2 certification.

Does Pfizer Medical comply with GDPR ?

According to Rankiteo, Pfizer Medical is not listed as GDPR compliant.

Does Pfizer Medical have PCI DSS certification ?

According to Rankiteo, Pfizer Medical does not currently maintain PCI DSS compliance.

Does Pfizer Medical comply with HIPAA ?

According to Rankiteo, Pfizer Medical is not compliant with HIPAA regulations.

Does Pfizer Medical have ISO 27001 certification ?

According to Rankiteo,Pfizer Medical is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Pfizer Medical operate in ?

Pfizer Medical operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Pfizer Medical have ?

Pfizer Medical employs approximately None employees people worldwide.

Does Pfizer Medical own any subsidiaries ?

Pfizer Medical presently has no subsidiaries across any sectors.

How many LinkedIn followers does Pfizer Medical have ?

Pfizer Medical's official LinkedIn profile has approximately followers.

What is the NAICS classification code for Pfizer Medical ?

Pfizer Medical is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Pfizer Medical have a Crunchbase profile ?

No, Pfizer Medical does not have a profile on Crunchbase.

Does Pfizer Medical have a LinkedIn profile ?

Yes, Pfizer Medical maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/pfizer-medical.

How many cybersecurity incidents has Pfizer Medical experienced ?

As of August 6, 2026, Rankiteo reports that Pfizer Medical has not experienced any cybersecurity incidents.

How many peer or competitor companies does Pfizer Medical have ?

Pfizer Medical has an estimated 5,724 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Pfizer Medical

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

Pfizer Medical Vendor Cyber Rating & Cyber Score

pfizer.com

Add Your Compliance Badge

The goal of the Pfizer Medical LinkedIn page is to communicate emerging, trusted scientific information. The PfizerMedical LinkedIn page and associated posts are intended only for healthcare professionals. By following this Pfizer Medical LinkedIn page, you confirm that you are a healthcare professional and agree to receive information relating to the scientific data provided. Please remember that your access to any social media channel is governed by its specific Terms of Service. Pfizer fully endorses the Terms of Service of all the social media services it uses, and it is important that you abide by them. As such, we reserve the right to report posts that we believe are in breach of the general LinkedIn Agreement

Pfizer Medical A.I CyberSecurity Scoring

Scoring History

Pfizer Medical

Pfizer Medical CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Pfizer Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Pfizer Medical

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incident Types Pfizer Medical vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incident History - Pfizer Medical (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Pfizer Medical Subsidiaries

Pfizer Medical

Pharmaceutical Manufacturing

Website: https://www.pfizer.com/products/information

Company Size: 10,001+ employees

PfizerPharmaceutical Manufacturing

Bamboo Therapeutics, Inc. a wholly owned subsidiary of Pfizer Inc.Biotechnology

Pfizer CentreOnePharmaceutical Manufacturing

Loading…

Pfizer Medical Similar Companies

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Loading…

NEWS

Pfizer Medical CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 07, 2025 07:00 AM

Missing Details On Trump’s Drug Price Plan Make It Hard To Evaluate

The Trump administration has reached an agreement with the drug company Pfizer to sell almost all of its medications to Medicaid at “most...

Read Article

October 03, 2025 07:00 AM

MAHA supporters not on board with Trump’s Pfizer deal

Proponents of Health and Human Services Secretary Robert F. Kennedy Jr.'s “Make America Healthy Again” (MAHA) agenda are outraged over the...

Read Article

October 02, 2025 07:00 AM

President announces TrumpRx and deal with Pfizer

The deal with Pfizer will reduce the price of the company's prescription drugs for Medicaid to Most Favored Nation pricing.

Read Article

September 03, 2025 07:00 AM

Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine

Sen. Bill Cassidy and Pfizer CEO Albert Bourla suggest President Trump deserves a Nobel Peace Prize for rapidly distributing the COVID-19...

Read Article

August 27, 2025 07:00 AM

FDA approves COVID-19 vaccines only for ‘high risk’ people

The Food and Drug Administration (FDA) on Wednesday approved the updated version of Pfizer's and Moderna's COVID-19 vaccines for this...

Read Article

August 21, 2025 07:00 AM

Article | The fall trip to the pharmacy for a Covid shot may be strewn with obstacles

The millions of Americans who are used to getting their Covid-19 vaccines at a local pharmacy may face new hurdles this fall depending on...

Read Article

August 16, 2025 07:00 AM

TOP 50 HEALTHCARE FUTURIST SPEAKERS: MEDICAL CONSULTING EXPERTS FOR EVENTS

Top 50 healthcare futurist speakers for events: Celebrity keynote Scott Steinberg, consultant to 3000 brands. AI telemedicine pharma medical...

Read Article

August 11, 2025 07:00 AM

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Cencora, The Lash Group, and their affiliates have agreed to pay $40 million to settle class action data breach litigation over a February...

Read Article

August 04, 2025 07:00 AM

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-67867

SUMMARY

Buffer Overflow vulnerability in Systerel S2OPC 1.7.3 allows a remote attacker to cause a denial of service via the Alarm/Conditions wrapper when processing PublishResponse EventNotificationList data

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67866

SUMMARY

Buffer Overflow vulnerability in Systerel S2OPC 1.7.3 allows a remote attacker to cause a denial of service via the LockedStaMac_ProcessMsg_DeleteMonitoredItemsResponse and SOPC_StaMac_NewDeleteMonitoredItems in the client wrapper DeleteMonitoredItems path

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67863

SUMMARY

In open62541 1.5.5, a server-side use-after-free exists in the local MonitoredItem callback path. The issue occurs when UA_Subscription_localPublish continues to use the current UA_Notification after a callback invokes UA_Server_deleteMonitoredItem for the current local MonitoredItem. This allows a remote attacker to cause a denial of service.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-19026

SUMMARY

H5Z__filter_nbit in H5Znbit.c in HDF5 through 2.3.0 dereferences cd_values[0] through cd_values[4] without validating that cd_values is non-NULL or that cd_nelmts is at least 5, the fixed size of the filter's header. This allows attackers to cause a denial of service via a crafted HDF5 file that stores the N-Bit filter pipeline message with zero client-data values, opened and read via H5Dread, e.g. by the h5ls or h5repack tools.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-19025

SUMMARY

H5O__layout_decode in H5Olayout.c in HDF5 through 2.3.0 does not validate that a chunked dataset's stored chunk-layout dimensionality matches its dataspace rank when an existing dataset is opened, whereas this check is performed only at dataset-creation time. This allows attackers to cause a denial of service (divide-by-zero and application crash in H5S__hyper_iter_get_seq_list in src/H5Shyper.c) via a crafted HDF5 file with mismatched chunk/dataspace ranks that is opened and read via H5Dopen2 and H5Dread, e.g. by the h5repack tool.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/HDFGroup/hdf5/issues/6491

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…